Protein Tyrosine Phosphatase Inhibition Prevents Experimental Cerebral Malaria by Precluding CXCR3 Expression on T

Kristin M Van Den Ham1,2, Logan K Smith1,3, Martin J Richer4,5

  • 1Department of Microbiology and Immunology, McGill University, Montréal, QC, H3A 0G4, Canada.

Scientific Reports
|July 16, 2017
PubMed

Insights

Inhibiting protein tyrosine phosphatase (PTP) activity reduces T cell brain infiltration and prevents cerebral malaria neuropathology. This PTP inhibition also enhances regulatory T cells, suggesting a potential therapeutic strategy for related diseases.

Area of Science:

  • Immunology
  • Neuroscience
  • Pathology

Background:

  • Cerebral malaria involves T cell brain sequestration and inflammation.
  • Plasmodium berghei ANKA infection models this severe condition.

Purpose of the Study:

  • To investigate the role of protein tyrosine phosphatase (PTP) activity in cerebral malaria.
  • To determine if PTP inhibition can prevent neuropathology.

Main Methods:

  • Studied T cell sequestration in the brain during Plasmodium berghei ANKA infection.
  • Assessed the impact of PTP inhibition on T cell responses and cytokine production.
  • Analyzed T cell-intrinsic PTP activity and regulatory T cell populations.

Main Results:

  • PTP inhibition significantly reduced T cell sequestration in the brain.
  • Neuropathology development was prevented by PTP inhibition.
  • PTP inhibition decreased CXCR3 upregulation on T cells.
  • Increased IL-10 production and frequency of type 1 regulatory cells were observed.

Conclusions:

  • Modulating PTP activity is a potential therapeutic approach for cerebral malaria.
  • PTP inhibition may offer benefits for other CXCR3-mediated diseases.